Duchenne Muscular Dystrophy Archives - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

Elevidys 3-Year Trial Data Show Sustained Outcomes in DMD Patients

January 30, 2026

Diagnostics News

HHS Expands Newborn Screening to Include Duchenne and MLD

December 19, 2025

FDA Places New Restrictions on Sarepta’s Elevidys Gene Therapy After DMD Patient Deaths

November 19, 2025

Novartis Acquires Avidity Biosciences for Late-Stage Muscular Dystrophy Assets in $12B Deal

October 31, 2025

Sarepta Cuts 36% of Workforce and Finally Agrees to FDA Request to Halt All Elevidys Shipments Following Patient Deaths

Sarepta’s Gene Therapy Elevidys Under Scrutiny After Patient Death

Best Pharma Innovations of 2024, According to TIME

November 7, 2024

GUARDIAN Study Reveals How Genomic Sequencing Could Bridge Gaps in Newborn Screening

October 29, 2024

Elixirgen Therapeutics’ Innovative Approach to mRNA Therapeutics

Italfarmaco’s Duvyzat Wins FDA Approval as First Nonsteroidal Treatment for All Genetic Variants of DMD

Sarepta’s Elevidys Reaches Finish Line as First Gene Therapy Approved for Duchenne Muscular Dystrophy

The Patient Experience Using MRI in DMD Clinical Trials — “Shed light through MRI”

Imaging for Neuromuscular Disorders in Clinical Trials

December 07, 2021

New CRISPR Gene Editing Enzyme Removed Duchenne Muscular Dystrophy Mutations

September 17, 2018

Watch Out Sarepta: Pfizer Initiates Trial of Duchenne Muscular Dystrophy Gene Therapy

August 30, 2018

Mallinckrodt Starts Phase II Duchenne Muscular Dystrophy Study but Will They Meet Recruitment Targets?

Next Page »